Yesterday, the Food and Drug Administration's (FDA) advisory committee met to discuss Merck's (MRK 0.07%) experimental insomnia drug Suvorexant. While the committee did agree that the drug was effective at lower doses, there were some concerns over the side-effects associated with the medication at higher doses. In the following video, health-care analyst Max Macaluso discusses the results of the meeting, and how the ultimate FDA decision on Suvorexant can impact Merck's stock.
The FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo